Locus Biosciences

Jul 19, 2018

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and…

Jan 19, 2018

NC State professor wins National Academy of Sciences prize in food, agriculture research

Dr. Rodolphe Barrangou, the Todd R. Klaenhammer Distinguished Scholar in Probiotics Research, University Scholar and associate professor in the NC State Department of Food, Bioprocessing and Nutrition Sciences, will receive the 2018 NAS…

Nov 15, 2017

NC State Startup Locus Biosciences Lands $19M in Funding for Gene Editing Technology

Locus Biosciences, born with the help of two loans from the North Carolina Biotechnology Center, has raised $19 million in Series A funding from major investors. The round was led…

Jul 17, 2017

Startup Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobials

Research Triangle Park-based Locus Biosciences has secured a $5 million convertible note. Chinese technology giant Tencent Holdings Limited led the financing round, which also included the N.C. Biotechnology Center. One…

Oct 27, 2016

NC State Startup Locus Biosciences featured in The Wall Street Journal

While Crispr-Cas9 has drawn a lot of attention, scientists are investigating other Crispr approaches that may reach doctors and patients more quickly.